2022
A randomized, phase II trial of oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence
Heumann T, Baretti M, Sugar E, Durham J, Linden S, Lopez-Vidal T, Leatherman J, Cope L, Sharma A, Weekes C, O’Dwyer P, Reiss K, Monga D, Ahuja N, Azad N. A randomized, phase II trial of oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence. Clinical Epigenetics 2022, 14: 166. PMID: 36463226, PMCID: PMC9719150, DOI: 10.1186/s13148-022-01367-8.Peer-Reviewed Original ResearchConceptsResectable pancreatic ductal adenocarcinomaCC-486OBS patientsMetastatic settingAdjuvant therapyTreatment-related grade 3Randomized phase II studyMedian age 66Next-line therapyResultsForty-nine patientsMedian treatment durationPhase II studyEvidence of diseaseHigh-risk featuresPhase II trialProgression-free survivalStandard adjuvant therapyPancreatic ductal adenocarcinomaCancer recursEvaluable patientsMedian OSMedian PFSOral azacitidineR1 resectionSubsequent chemotherapy
2008
Pancreatic Resection of Isolated Metastases from Nonpancreatic Primary Cancers
Reddy S, Edil BH, Cameron JL, Pawlik TM, Herman JM, Gilson MM, Campbell KA, Schulick RD, Ahuja N, Wolfgang CL. Pancreatic Resection of Isolated Metastases from Nonpancreatic Primary Cancers. Annals Of Surgical Oncology 2008, 15: 3199-3206. PMID: 18784960, DOI: 10.1245/s10434-008-0140-7.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaPancreatic resectionMetachronous lesionsMetastatic lesionsVascular invasionConclusionLong-term survivalResultsForty-nine patientsLymph node metastasisLangerhans cell histiocytosisDistal pancreatectomyPerioperative deathsPostoperative morbidityTotal pancreatectomyIsolated metastasisMedian survivalMetastatic diseaseSynchronous lesionsNode metastasisPrimary diseasePrimary cancerMedian lengthCell carcinomaGallbladder cancerSingle institutionCell histiocytosis